Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

ANCA Mortality: Are Patients Doing Better?

Lara C. Pullen, PhD  |  December 13, 2019

Patients with anti-neutrophil cytoplasmic antibody–associated vasculitides (AAV) have an increased risk of mortality. But treatments have evolved in recent years. Recent research found that between 1999 and 2017 the AAV mortality rate declined by nearly 2% per year in patients 65–74 years old…

Filed under:ConditionsVasculitis Tagged with:ANCAanti-neutrophil cytoplasmic antibodies (ANCA)mortality

Depression in Ankylosing Spondylitis: Mastery Is Key

Lara C. Pullen, PhD  |  December 13, 2019

A recent study indicates that depression in patients with ankylosing spondylitis is a result of both contextual and disease-related factors. Researchers found a patient’s mastery—the perception they have control over things in their lives—plays a key role in the development of depression in this patient population…

Filed under:Axial SpondyloarthritisConditions Tagged with:Ankylosing SpondylitisDepressionmastery

Pegloticase & Methotrexate Combination Therapy May Benefit Patients with Uncontrolled Gout

Michele B. Kaufman, PharmD, BCGP  |  December 11, 2019

Patients with uncontrolled gout may benefit from a combination of pegloticase and methotrexate therapy, according to a small, retrospective study…

Filed under:ConditionsDrug UpdatesGout and Crystalline Arthritis

Hriana / shutterstock.com

ACR Publishes Disease Activity and Functional Status Assessment Measure Recommendations for RA

Mary Beth Nierengarten  |  December 10, 2019

The recommendations include updated disease activity measures and a new set of functional status assessment measures for rheumatoid arthritis.

Filed under:Clinical Criteria/GuidelinesRheumatoid Arthritis Tagged with:disease activity measuresDr. Bryant EnglandDr. Claire BarberDr. Kaleb Michaudfunctional status assessment measuresrecommendations

Spotlight on Ethics & Conflicts of Interest: A Conversation with Karen Onel, MD, New Chair of the ACR’s Ethics Committee

Vanessa Caceres  |  December 8, 2019

Karen Onel, MD, new chair of ACR’s Committee on Ethics & Conflict of Interest, brings a longstanding interest in issues related to ethics and consent.

Filed under:American College of RheumatologyEthics Tagged with:Conflict of interestEthicsKaren Onel

Tildrakizumab Promising for Psoriasis in Patients with PsA

Michele B. Kaufman, PharmD, BCGP  |  December 2, 2019

New research shows tildrakizumab may significantly improve psoriasis in patients with active psoriatic arthritis…

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:2019 ACR/ARP Annual MeetingPsoriasisPsoriatic Arthritistildrakizumab

How to Address Opioid Abuse with Patients

Carina Stanton  |  December 2, 2019

More than half of regular opioid users suffer from arthritis. Here are three tips to talk to your patients about opioid use and alternative pain management…

Filed under:Drug Updates Tagged with:Opioid abuseopioid alternativesPain Managementpatient communicationphysician-patient communication

New Consensus Recommendations Guide Sjögren’s Syndrome Management

Will Boggs, MD  |  November 25, 2019

NEW YORK (Reuters Health)—New consensus-based recommendations from the European League Against Rheumatism (EULAR) address the management of Sjögren’s syndrome with topical and systemic therapies. Sjögren’s syndrome presents with a broad spectrum of clinical manifestations and autoantibodies, including antinuclear antibodies (the most frequently detected), anti-Ro/SS-A (the most specific) and cryoglobulins and hypocomplementemia (the main prognostic markers)….

Filed under:ConditionsEULAR/OtherMeeting ReportsSjögren’s Disease Tagged with:EULARguidelinerecommendationsSjogren's

Rituximab-abbs Available in the U.S.; Plus Upadacitinib in Phase 3 Trials for PsA

Michele B. Kaufman, PharmD, BCGP  |  November 25, 2019

Rituximab-abbs, which is biosimilar to rituximab, is now available in the U.S. to treat specific cancers…

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:Cancernon-Hodgkin’s lymphomaPsoriatic Arthritisrituximabrituximab-abbsupadacitinib

Progress on Preventing Immune-Related Adverse Events

Mike Fillon  |  November 20, 2019

ATLANTA—One of the hottest topics in medicine is the emerging field of cancer immunotherapy. However, immune-related adverse events (irAEs) are associated with the therapy, and when things go wrong, they can go very, very wrong, said Ryan Sullivan, MD, during the 2019 ACR/ARP Annual Meeting in November. “The guiding principle of cancer immunotherapy is [that]…

Filed under:Conditions Tagged with:2019 ACR/ARP Annual MeetingBiomarkersCancerCheckpoint Inhibitorsimmune-related adverse events

  • « Previous Page
  • 1
  • …
  • 110
  • 111
  • 112
  • 113
  • 114
  • …
  • 323
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences